RENOVORX INC (RNXT) Stock Price, Quote, News and Overview
NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD
RNXT Quote, Performance and Key Statistics
NASDAQ:RNXT (5/8/2025, 9:51:13 AM)
1.05
0 (0%)
The current stock price of RNXT is 1.05 USD. In the past month the price increased by 31.87%. In the past year, price decreased by -27.24%.
RNXT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.78 | 323.02B | ||
| AMGN | AMGEN INC | 12.85 | 143.42B | ||
| GILD | GILEAD SCIENCES INC | 12.45 | 119.94B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.87 | 56.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.16B | ||
| ARGX | ARGENX SE - ADR | 283.3 | 32.87B | ||
| ONC | BEIGENE LTD-ADR | 5.83 | 25.20B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.34B | ||
| NTRA | NATERA INC | N/A | 21.75B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.01B | ||
| BIIB | BIOGEN INC | 7.39 | 17.14B |
Related stock screener links
About RNXT
Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. The company is headquartered in Mountain View, California and currently employs 10 full-time employees. The company went IPO on 2021-08-17. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Company Info
RENOVORX INC
2570 W. El Camino Real, Ste. 320,
Mountain View CALIFORNIA US
CEO: Shaun R. Bagai
Employees: 10
Phone: 14088002649
RENOVORX INC / RNXT FAQ
What is the stock price of RENOVORX INC today?
The current stock price of RNXT is 1.05 USD.
What is the ticker symbol for RENOVORX INC stock?
The exchange symbol of RENOVORX INC is RNXT and it is listed on the Nasdaq exchange.
On which exchange is RNXT stock listed?
RNXT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RENOVORX INC stock?
10 analysts have analysed RNXT and the average price target is 5.44 USD. This implies a price increase of 418.09% is expected in the next year compared to the current price of 1.05. Check the RENOVORX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RENOVORX INC worth?
RENOVORX INC (RNXT) has a market capitalization of 38.38M USD. This makes RNXT a Nano Cap stock.
How many employees does RENOVORX INC have?
RENOVORX INC (RNXT) currently has 10 employees.
What are the support and resistance levels for RENOVORX INC (RNXT) stock?
RENOVORX INC (RNXT) has a support level at 1.04 and a resistance level at 1.27. Check the full technical report for a detailed analysis of RNXT support and resistance levels.
Should I buy RENOVORX INC (RNXT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNXT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNXT, evaluating the profitability, health, valuation and growth aspects
- RENOVORX INC (RNXT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RENOVORX INC (RNXT) Sales and EPS estimates to see what analysts future expectations are.
- RENOVORX INC (RNXT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RENOVORX INC (RNXT) Insider and Institutional Ownership to learn about the owners and their transactions.
- RENOVORX INC (RNXT) Stock Chart to make your own analysis
- RENOVORX INC (RNXT) Latest news and press-releases to stay up to date.
Does RENOVORX INC (RNXT) stock pay dividends?
RNXT does not pay a dividend.
When does RENOVORX INC (RNXT) report earnings?
RENOVORX INC (RNXT) will report earnings on 2025-05-19.
What is the Price/Earnings (PE) ratio of RENOVORX INC (RNXT)?
RENOVORX INC (RNXT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
What is the Short Interest ratio of RENOVORX INC (RNXT) stock?
The outstanding short interest for RENOVORX INC (RNXT) is 0.82% of its float. Check the ownership tab for more information on the RNXT short interest.
RNXT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to RNXT. When comparing the yearly performance of all stocks, RNXT is a bad performer in the overall market: 76.02% of all stocks are doing better.
RNXT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNXT. The financial health of RNXT is average, but there are quite some concerns on its profitability.
RNXT Financial Highlights
Over the last trailing twelve months RNXT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 63.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.57% | ||
| ROE | -196.83% | ||
| Debt/Equity | 0 |
RNXT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RNXT. The Buy consensus is the average rating of analysts ratings from 10 analysts.